Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DefenCath in Reducing CLABSIs in Patients Receiving TPN
NCT06822426Phase 3Recruiting
- Sponsor
- CorMedix Inc.
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Implantable Devices, Transdermal Patches, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Heparina cálcica in central line-associated bloodstream infection (CLABSI) (2 arms), sponsored by CorMedix Inc. Primary endpoint: Proportion of participants who experience a Central Line-Associated Bloodstream Infection at 12 months. Started May 2025; status: recruiting.
02
Drugs
Heparina cálcica
03
Conditions
central line-associated bloodstream infection (CLABSI)
Beyond the preview
Go deeper on NCT06822426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822426.